EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Neurocrine Biosciences, Inc. (NBIX) had EBIT Margin of 26.18% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$805.50M |
|
$153.70M |
|
$17.60M |
|
$787.90M |
|
$594.60M |
|
$210.90M |
|
$28.50M |
|
$239.40M |
|
$236.70M |
|
$153.70M |
|
$153.70M |
|
$153.70M |
|
$144.58M |
|
$210.90M |
|
$205.70M |
|
99.50M |
|
102.50M |
|
$1.53 |
|
$1.49 |
|
| Balance Sheet Financials | |
$2.52B |
|
$89.80M |
|
$2.11B |
|
$4.63B |
|
$743.40M |
|
-- |
|
$635.00M |
|
$1.38B |
|
$3.25B |
|
$3.25B |
|
$3.25B |
|
100.10M |
|
| Cash Flow Statement Financials | |
$782.70M |
|
$-264.40M |
|
$-38.30M |
|
$241.00M |
|
$721.00M |
|
$480.00M |
|
$217.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
97.81% |
|
26.18% |
|
|
EBIT Margin |
26.18% |
-- |
|
29.72% |
|
19.08% |
|
$748.70M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.26 |
|
1.17 |
|
76.74 |
|
4.72% |
|
4.72% |
|
3.32% |
|
4.72% |
|
$32.50 |
|
$7.30 |
|
$7.64 |
|